^
Association details:
| Biomarker: | IFNG 6-gene signature |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
Excerpt:
Further evaluation of the refined signatures was performed in 43 patients with head and neck squamous cell carcinoma (HNSCC) and 33 patients with gastric cancer enrolled in the Phase 1b KEYNOTE-012 study….The IFN-γ signature was refined from 10 genes to 6, and the expanded immune signature from 28 genes to 18...All signatures were independently tested in HNSCC and gastric cancer and found to be significantly correlated with clinical benefit...
DOI:
10.1186/2051-1426-3-S2-P80
Trial ID:
